Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06677307 | A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | PHASE1 | TERMINATED | 42 | — | — | Jan 13, 2025 | Dec 15, 2025 | Apr 17, 2026 | 5 | Australia, New Zealand |
Type, frequency, and severity of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Arm 1: KRRO-110 (Part A and Part B) | EXPERIMENTAL | KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD). |
| Arm 2: Placebo (Part A only) | PLACEBO_COMPARATOR | Placebo, IV administration |
| Name | Type | Description |
|---|---|---|
| KRRO-110 | DRUG | KRRO-110 drug product, IV |
Inclusion Criteria: Part A SAD cohort Inclusion Criteria (Healthy Volunteers) * Adult male or female participants, 18 to 65 years of age * Documented PiMM genotype * Participants who are willing to and able to provide signed written informed consent PiZZ Genotype (Part A SAD and Part B MAD cohort...